Lexaria Bioscience says has received four new patents
Lexaria Bioscience announced that four of its pending patent applications, via its wholly-owned subsidiary Poviva Corp., have now been granted. The four new patents granted are as follows: Methods for formulating orally ingestible compositions comprising lipophilic active agents as well as Food and beverage compositions infused with lipophilic active agents and methods of use thereof. The issuance of these four patents results in Lexaria's total patents granted increasing to 15 with eight granted in the US and seven granted in Australia, along with roughly 60 patent applications pending throughout the world. The granted patents cover delivery of: cannabinoids such as THC and CBD; NSAIDs such as ibuprofen; nicotine; and vitamins.